Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India

pdf

Torrent Pharmaceuticals Ltd.

30 May 2024

3549.50

0.03%

Earnings Call

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of Conference Call with Analysts / Investors on Audited Financial Results for the quarter and year ended 31st March, 2024

pdf

Torrent Pharmaceuticals Ltd.

29 May 2024

3549.50

0.03%

Company Update

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copies of Newspaper cuttings in connection with transfer of shares to IEPF.

pdf

Torrent Pharmaceuticals Ltd.

24 May 2024

3549.50

0.03%

Company Update

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Resignation of Director

BSE India

In continuation to our earlier letter dated 24-May-24 intimating the desire of Jinesh Shah to step down as the Director of the Company effective from 23-Jul-24, please find the letter attached herewith received from Jinesh Shah as Annexure 1 in this respect

pdf

Torrent Pharmaceuticals Ltd.

24 May 2024

3549.50

0.03%

Earnings Call

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

In continuation to our letter dated 10-May-24 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2024, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording31032024.mp3

pdf